The current Act requires a person who has obtained marketing approval and an importer to indicate the name, manufacturing number and effective period or time limit for use, etc. of drugs on the containers or packages of the drugs, and the Ordinance of the Prime Minister prescribes the indications of the name, etc. of drugs to be marked in braille as well. 

However, the drug indications in braille for visually impaired persons are just recommendations. Only a few drugs include indications in braille, exposing visually impaired persons and their offspring to the risk of drug misuse or abuse.

Hence, this Amendment requires information regarding safe and readily available drugs to be indicated in braille or braille/text-to-speech code in order to enhance drug accessibility of visually impaired persons and prevent their misuse or abuse thereof (Article 59-2, Article 98, paragraph 1, subparagraph 7-4 newly inserted).

Oblige information regarding safe and readily available drugs to be indicated in braille or braille/text-to-speech code and impose an administrative fine on violations of this provision (Article 59-2, Article 98, paragraph 1, subparagraph 7-4 newly inserted)